The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate

doi:10.1016/S0149-2918(01)80061-8

Clinical Therapeutics

Volume 23, Issue 4, April 2001, Pages 578-584

https://doi.org/10.1016/S0149-2918(01)80061-8 Get rights and content

Abstract

Background: A new oral pharmacokinetically enhanced formulation of the broad-spectrum antibiotic amoxicillin/clavulanate has been developed to provide more effective therapy against resistant pathogens than is provided by currently available formulations by maintaining therapeutically useful plasma amoxicillin concentrations for a longer period after dosing.

Objective: This study explored the pharmacokinetics of the new oral formulation of amoxicillin/clavulanate in healthy male and female subjects.

Methods: A single oral dose of pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg; 16:1 ratio) was administered to subjects at the start of a meal. After dosing, blood samples were collected at frequent intervals up to 12 hours, and plasma was assayed for amoxicillin and clavulanate concentrations using validated procedures. The new formulation consisted of 1 layer of immediate-release amoxicillin and clavulanate and another of sustained-release amoxicillin in a proportion such that for an amoxicillin minimum inhibitory concentration (MIC) of 4 μg/mL, the time above the MIC (T > MIC) would be approximately ≥40% over a 12-hour dosing interval.

Results: The study enrolled 24 and 31 healthy male and female subjects, respectively. Their mean age was 35 years (range, 18–58 years) and mean body weight was 69 kg (range, 51–86 kg). After the expected sharp peak in plasma amoxicillin concentration, there appeared to be a slower decline with the pharmacokinetically enhanced formulation than is usually seen with conventional formulations, and there was evidence of a second amoxicillin absorption phase. The mean T > MIC for an amoxicillin MIC of 4 μg/mL was 49.4% of a 12-hour dosing interval, a value that cannot be achieved with existing approved doses and formulations of amoxicillin/clavulanate. By 12 hours, plasma amoxicillin concentrations were very low (∼0.05 μg/mL), suggesting no expectation of notable dose-to-dose accumulation on repeat dosing with a BID regimen. The terminal half-lives of amoxicillin (1.27 hours) and clavulanate (1.03 hours) with the new formulation were similar to those of existing formulations of amoxicillin/clavulanate. No deaths or serious adverse events were reported.

Conclusions: The enhanced pharmacokinetic profile of amoxicillin/clavulanate seen in this study suggests that this formulation is likely to be highly effective for the oral treatment of infections caused by bacteria—including beta-lactamase—producing organisms—and strains with amoxicillin MICs ≤4 μg/mL.

References (6)

CT Dollery
CT Dollery
PA Todd et al.
Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use
Drugs
(1990)

There are more references available in the full text version of this article.

Cited by (86)

Primary lung abscess caused by Staphylococcus lugdunensis
2017, Journal of Infection and Chemotherapy
Citation Excerpt :
The standard intravenous dosage of amoxicillin/clavulanate is 1000/200 mg every 8 hours for the treatment of community-acquired lower respiratory tract infections [14]. To treat drug-resistant Streptococcus pneumoniae or β-lactamase-producing bacteria (e.g., Haemophilus influenzae and Moraxella catarrhalis), a high-dosage of 2000/125 mg twice daily for adults has been developed with an extended-release amoxicillin component that enhances the pharmacokinetics of this formulation and covers of more bacterial strains than does conventional dosing [14,15]. In our case, β-lactamase was detected in S. lugdunensis.
Staphylococcus lugdunensis, a strain of coagulase–negative staphylococci, is part of the normal flora of human skin but can cause multiple infections at various sites. This microorganism has emerged as a major human pathogen. However, no study has reported primary lung abscess caused by S. lugdunensis. A 54-year-old alcoholic man without relevant past medical history was admitted because of primary lung abscesses. Empirical amoxicillin/clavulanate therapy was initially administered; however, the patient had persistent pleuritic chest pain and fever. He subsequently underwent resection of the lung abscess and removal of exudative pleural effusion on the fourth hospital day. Histopathologic examination confirmed the diagnosis of lung abscess, and colonies of gram-positive bacteria were identified. The culture specimen from the abscess was positive for S. lugdunensis, which was susceptible to amoxicillin/clavulanate, cefazolin, ciprofloxacin, clindamycin, erythromycin, oxacillin, teicoplanin, tetracycline, and vancomycin. Following resection and 3 weeks of amoxicillin/clavulanate therapy, the patient eventually recovered well without relapse. This case report is the first to describe S. lugdunensis as a cause of primary lung abscess; this microorganism should be considered a potential monomicrobial pathogen in primary lung abscess.
Bioavailability of amoxicillin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying
2008, European Journal of Pharmaceutics and Biopharmaceutics
The rate and extent of amoxicillin and clavulanic acid absorption from pharmacokinetically enhanced extended release (ER) tablets is strongly influenced by the intake conditions. In order to investigate the cause of the food effects, a pharmacokinetic study with simultaneous imaging of the in vivo behaviour of the ER tablets by magnetic marker monitoring (MMM) was performed. Under fasting conditions the amoxicillin AUC (1854 ± 280 μg min ml⁻¹) was significantly lower than after intake at the beginning of the breakfast (2452 ± 354 μg min ml⁻¹) or after the breakfast (2605 ± 446 μg min ml⁻¹). In contrast, clavulanic acid AUC was well comparable after tablet intake under fasting conditions and intake at the beginning of a breakfast (191 ± 46 and 189 ± 44 μg min ml⁻¹, respectively) but significantly lower following a breakfast (126 ± 71 μg min ml⁻¹). The localization data showed that the reduced bioavailability of amoxicillin under fasting conditions is due to early gastric emptying in combination with poor absorption from deeper parts of the small intestine. Prolonged gastric residence of clavulanic acid caused by intragastric tablet deposition in the proximal stomach was identified as the reason for the decreased bioavailability of clavulanic acid after tablet intake following the meal.
The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults
2007, International Journal of Antimicrobial Agents
Rising levels of resistance amongst the major respiratory pathogens have compromised empiric antimicrobial therapy. This, coupled with a recent lack in availability of novel classes of antibacterials, has led to a need for new approaches to combat community respiratory tract infections. Bacteriological and clinical efficacy in two trials involving patients with acute bacterial sinusitis and six trials of patients with community-acquired pneumonia has shown that the development of a pharmacokinetically enhanced formulation of amoxicillin/clavulanate (Augmentin SR, available as Augmentin XR in the USA) has allowed amoxicillin/clavulanate to retain its place in the treatment of respiratory tract infections today.
Combating resistance: application of the emerging science of pharmacokinetics and pharmacodynamics
2007, International Journal of Antimicrobial Agents
During the last 10–15 years understanding of relationships between pharmacokinetic (PK) and pharmacodynamic (PD) parameters and bacteriological and clinical outcomes has expanded allowing correlation between in vitro potency and in vivo efficacy. PK and PD principles can be applied to development of new antibacterials and formulation of existing agents to help address the increasing prevalence of antibacterial resistance. For beta-lactams, such as penicillins, the unbound serum concentration of the drug exceeding the minimum inhibitory concentration of the causative pathogen for 40–50% of the dosing interval is predictive of bacteriologic efficacy (bacterial eradication) and can be used to determine a PK/PD breakpoint for that specific dosing regimen. Amoxicillin/clavulanate was one of the earliest antibacterials to use the unique approach of PK/PD principles to develop new and enhanced formulations, allowing it to remain a significant antibacterial agent in the management of respiratory tract infections.
Simultaneous determination of amoxicillin and clavulanic acid in human plasma by isocratic reversed-phase HPLC using UV detection
2007, Journal of Pharmaceutical and Biomedical Analysis
A simple, rapid and sensitive isocratic reversed phase HPLC method with UV detection using internal standard has been developed and validated for simultaneous determination of amoxicillin and clavulanic acid in human plasma. The assay enables the measurement of amoxicillin and clavulanic acid for therapeutic drug monitoring with a minimum quantification limit of 15 and 30 ng ml⁻¹, respectively. The method involves simple, one-step extraction procedure and analytical recovery was complete. The separation was carried out in reversed-phase conditions using a Chromolith Performance (RP-18e, 100 mm × 4.6 mm) column with an isocratic mobile phase consisting of 0.02 M disodium hydrogen phosphate buffer–methanol (96:4, v/v) adjusted to pH 3.0. The wavelength was set at 228 nm. The coefficients of variation for inter-day and intra-day assay were found to be less than 9.0%.
Population pharmacokinetics and dosing simulations of amoxicillin in obese adults receiving co-amoxiclav
2020, Journal of Antimicrobial Chemotherapy

View all citing articles on Scopus

View full text

The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate

Abstract

Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use

Drugs